Form 4: RAPT Therapeutics Director Wendye Robbins Acquires Stock Options
SEC Form 4 Filing
Wendye Robbins, a director at RAPT Therapeutics, acquired stock options for 36,490 shares of common stock on May 22, 2024.
Summary
- On May 22, 2024, Wendye Robbins, a director of RAPT Therapeutics, acquired stock options to purchase 36,490 shares of the company's common stock.
- The exercise price of these options is $4.63 per share.
- The options vest in 12 equal monthly installments from the grant date and expire on May 21, 2034.
- The transaction was reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It reflects insider activity, which can be interpreted as a sign of confidence, but it's not inherently positive or negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option grant and transaction. |
| 05/21/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.